Lifecore Biomedical, Inc. (LFCR) — Financial statements
Income statement, balance sheet, and cash flow for Lifecore Biomedical, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 129↑0.5% | 128↑24.2% | 103↓7.2% | 111↑10.3% | 101 | |
| Cost of Revenue | 89↑2.5% | 86↑14.8% | 75↑4.3% | 72↑16.6% | 62 | |
| Gross Profit | 40↓3.7% | 42↑49.5% | 28↓28.4% | 39↑0.3% | 39 | |
| Operating Expenses | ||||||
| R&D Expenses | 8↓3.7% | 9↓1.8% | 9↑11.4% | 8↑17.3% | 7 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 44↑8.9% | 40↑3.8% | 39↑12.4% | 35↑25.0% | 28 | |
| Other Expenses | 5↑216.4% | 2↓20.2% | 2↓75.2% | 8↓37.4% | 13 | |
| Operating Expenses | 58↑13.5% | 51↑1.8% | 50↓2.1% | 51↑6.5% | 48 | |
| Total Costs & Expenses | 146↑6.6% | 137↑9.6% | 125↑1.6% | 123↑12.2% | 110 | |
| Operating Results | ||||||
| Operating Income | -17↓95.0% | -9↑59.4% | -22↓84.9% | -12↓33.6% | -9 | |
| Depreciation & Amortization | 8↑0.3% | 8↓39.3% | 13↓27.0% | 18↓9.1% | 20 | |
| EBITDA | -9↓124.8% | 36↑207.3% | -33↓358.3% | 13↑1401.3% | -0.99 | |
| EBIT | -17↓161.0% | 28↑159.6% | -46↓788.4% | -5↑75.0% | -21 | |
| Interest & Other Income | ||||||
| Net Interest Income | -22↓20.7% | -18↓2.9% | -18↓13.6% | -15↓74.1% | -9 | |
| Interest Income | 0.00 | 0.00↓100.0% | 0.07↓16.0% | 0.08↑68.8% | 0.05 | |
| Interest Expense | 22↑20.7% | 18↑2.5% | 18↑13.5% | 16↑74.1% | 9 | |
| Non-Operating Income | -0.41↑98.9% | -36↓248.5% | 25↑473.5% | -7↓154.6% | 12 | |
| Other Income / Expenses | -21↓216.7% | 18↑143.6% | -42↓373.6% | -9↑57.6% | -21 | |
| Income Before Tax | -39↓506.5% | 10↑114.9% | -64↓209.0% | -21↑30.6% | -30 | |
| Income Tax Expense | 0.04↓76.5% | 0.18↓40.6% | 0.31↑105.9% | -5↑17.9% | -6 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -39↓514.9% | 9↑114.5% | -64↓315.1% | -15↑34.0% | -23 | |
| Net Income from Discontinued Operations | 0.00↓100.0% | 3↑107.6% | -35↑65.1% | -101↓1043.0% | -9 | |
| Net Income | -39↓422.3% | 12↑112.1% | -100↑14.7% | -117↓261.4% | -32 | |
| Bottom-Line Net Income | -44↓469.3% | 12↑112.1% | -100↑14.7% | -117↓261.4% | -32 | |
| EPS (Basic) | -1.27↓425.6% | 0.39↑111.7% | -3.32↑16.4% | -3.97↓254.5% | -1.12 | |
| EPS (Diluted) | -1.27↓484.8% | 0.33↑109.9% | -3.32↑16.4% | -3.97↓254.5% | -1.12 | |
| Weighted Average Shares | 35↑14.3% | 30↑1.7% | 30↑1.7% | 29↑0.6% | 29 | |
| Weighted Average Diluted Shares | 35↓5.0% | 37↑22.4% | 30↑1.7% | 29↑0.6% | 29 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.